Principia Announces Positive Data from its Phase 2 Part B Trial in Pemphigus
Clear dose-response combined with decreased daily corticosteroid usage Response rate increased with extended duration of treatment to six months while maintaining a favorable safety profile SOUTH SAN FRANCISCO, Calif., June 12, 2020 (GLOBE NEWSWIRE) -- …